Arvinas (ARVN) Stock Forecast, Price & News

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARVN shares.
View ARVN analyst ratings or view top-rated stocks.

16 brokers have issued 12-month price objectives for Arvinas' stock. Their ARVN share price forecasts range from $27.00 to $95.00. On average, they anticipate the company's stock price to reach $67.33 in the next twelve months. This suggests a possible upside of 207.5% from the stock's current price.
View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts.

Arvinas' stock was trading at $34.21 on January 1st, 2023. Since then, ARVN stock has decreased by 36.0% and is now trading at $21.90.
View the best growth stocks for 2023 here.

Arvinas saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 3,670,000 shares, a decrease of 10.9% from the April 30th total of 4,120,000 shares. Based on an average trading volume of 445,800 shares, the short-interest ratio is presently 8.2 days. Approximately 8.0% of the company's shares are short sold.
View Arvinas' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ARVN earnings forecast.

Arvinas, Inc. (NASDAQ:ARVN) issued its quarterly earnings data on Friday, May, 5th. The company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($1.49) by $0.05. The business had revenue of $32.50 million for the quarter, compared to analyst estimates of $27.74 million. Arvinas had a negative net margin of 227.86% and a negative trailing twelve-month return on equity of 50.85%. Arvinas's revenue was up 22.6% on a year-over-year basis. During the same period last year, the business earned ($1.20) EPS.

ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC), Harbor Disruptive Innovation ETF (INNO) and BlackRock Future Health ETF (BMED).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Arvinas' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (10.71%), BlackRock Inc. (8.38%), EcoR1 Capital LLC (6.96%), Price T Rowe Associates Inc. MD (4.71%), ArrowMark Colorado Holdings LLC (2.94%) and State Street Corp (2.07%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends.

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARVN stock can currently be purchased for approximately $21.90.

Arvinas (NASDAQ:ARVN) has a market capitalization of $1.17 billion and generates $137.40 million in revenue each year. The company earns $-282,500,000.00 in net income (profit) each year or ($5.66) on an earnings per share basis.

The company employs 280 workers across the globe.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.